Enzyme inhibitors for metabolic redirection

A method of inhibiting metabolism of a drug administered to a mammalian subject, comprising

• co-administering with said drug a morpholino antisense oligomer effective to reduce expression of a cytochrome p450 enzyme that catalyzes metabolism of the drug in said subject, by hybridizing to a target RNA molecule which encodes said enzyme;
• wherein the cytochrome p450 is selected from the group consisting of CYP2B1, CYP2E1, CYP3A2, and CYP3A4;
• and wherein said morpholino oligomer:
• is composed of morpholino subunits, linked together by uncharged phosphorus-containing linkages, one to three atoms long, joining the morpholino nitrogen of one subunit to the 5′ exocyclic carbon of an adjacent subunit, and includes, linked to each subunit, a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and has a base sequence selected from the group consisting of:
• SEQ ID NO:
• 16, for inhibition of CYP2B1, SEQ ID NOs:
• 18-20 and 23, for inhibition of CYP2E1, SEQ ID NOs:
• 24 and 25, for inhibition of CYP3A2, and SEQ ID NOs:
• 35, 46, and 47, for inhibition of CYP3A4.